Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Adult Soft Tissue Sarcoma: early-phase trial registry
1 of 12 indexed Recurrent Adult Soft Tissue Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 1 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Recurrent Adult Soft Tissue Sarcoma: 12 US clinical trials tracked, 1 recruiting.
Recurrent Adult Soft Tissue Sarcoma is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition recurrent-adult-soft-tissue-sarcoma
OPEN 1 | RECR 8% | LATE 0 | EARLY 9 | RANK #1429 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Allergic Rhinitis (8% recruiting · 24 trials)
Recurrent Adult Soft Tissue Sarcoma lists 1 open slots (8% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Adult Soft Tissue Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Adult Soft Tissue Sarcoma is recruiting below its size-band peers.
1 of 12 indexed trials (8.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Adult Soft Tissue Sarcoma research.
National Cancer Institute (NCI) accounts for 6 of 12 trials (50%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Adult Soft Tissue Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 12 trials that report a genuine target (sentinel values excluded). 8 of those (66.7%) plan for fewer than 100 participants.
-
Recurrent Adult Soft Tissue Sarcoma research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Jonsson Comprehensive Cancer Center
NCT02701153
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
NCT02357810
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Children's Oncology Group
NCT00919269
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
NCT00245102
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT00331643
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
National Cancer Institute (NCI)
NCT01222715
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
NCT01653028
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Northwestern University
NCT01782313
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
NCT00087074
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01553539
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Ann & Robert H Lurie Children's Hospital of Chicago
NCT01586104
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
NCT00937495
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Adult Soft Tissue Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Adult Soft Tissue Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Adult Soft Tissue Sarcoma page
12 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Adult Soft Tissue Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Adult Soft Tissue Sarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Adult Soft Tissue Sarcoma condition card totals 12 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.